Subpotent Oral Solution Prompts Recall of Hypothyroidism Treatment
The use of recalled products may lead to signs and symptoms of hypothyroidism.
The use of recalled products may lead to signs and symptoms of hypothyroidism.
A recent posting on the FDA’s Drug Shortages tracker indicates that the product has been discontinued.
Tirosint-SOL is approved for the treatment of hypothyroidism and for pituitary thyrotropin suppression.
The prescription-only device works with integrated continuous glucose monitors and alternate controller enabled pumps.
The approval was based on data from a clinical program that included 23 clinical trials enrolling more than 5000 adults with type 2 diabetes mellitus.
Dexcom G7 offers new features with a 60% smaller, discreet wearable patch.
The trial evaluated the efficacy and safety of empagliflozin and linagliptin in 175 patients 10 to less than 18 years of age with type 2 diabetes.
TransCon PTH is an investigational once-daily long-acting prodrug of parathyroid hormone (PTH[1-34]) designed to restore physiologic levels of PTH for 24 hours each day.
To date, the Company has not received any reports of adverse reactions related to this recall.
The multicenter, randomized, controlled GRADE study was designed to compare the effectiveness of 4 major FDA-approved medications.